Item | All | SEA and COPD | SEA | p-value |
Subjects | 84 | 42 (50) | 42 (50) | |
Age years | 61 (55–66) | 61 (55–65) | 61 (55–66) | 0.917 |
Sex | ||||
Female | 34 (41) | 17 (41) | 17 (41) | 1.000 |
Male | 50 (59) | 25 (59) | 25 (59) | |
BMI kg·m−2 | 29 (25–34) | 28 (25–34) | 29 (25–34) | 0.512 |
Therapy | ||||
Anti-IL-5 (mepolizumab) | 35 (42) | 23 (55) | 12 (29) | 0.015# |
Anti-IL-5Rα (benralizumab) | 49 (58) | 19 (45) | 30 (71) | |
OCS | 43 (51) | 23 (55) | 20 (48) | 0.513# |
ICS, medium–high dose | 100 (100) | 42 (100) | 42 (100) | 1.000# |
IL-5 responder | 64 (76) | 32 (76) | 32 (76) | 1.000# |
Smoking | ||||
Never | 28 (33) | 0 (0) | 28 (67) | <0.001# |
Former | 56 (67) | 42 (100) | 14 (33) | |
Pack-years | 20 (9–30) | 20 (15–30) | 7 (4–9) | <0.001 |
PFT | ||||
DLCO % predicted | 79 (72–97) | 74 (70–90) | 94 (75–101) | 0.116 |
KCO % predicted | 107 (89–115) | 93 (80–112) | 112 (105–117) | 0.005 |
FEV1/FVC post-BDT | 66 (54–73) | 66 (58–73) | 68 (51–73) | 0.785 |
Positive bronchodilator test¶ | 21 (38) | 13 (43) | 8 (31) | 0.333# |
Total IgE IU·mL−1 | 177 (74–751) | 446 (87–1442) | 126 (41–259) | 0.040 |
CT imaging, mean±sd+ | ||||
Total lung volume mL | 5878±1479 | 6041±1461 | 5681±1515 | 0.427 |
LAA-950 cc | 188±379 | 271±494 | 88±101 | 0.113 |
LAA-950 % | 2.8±5.2 | 3.9±6.7 | 1.4±1.6 | 0.099 |
Comorbidities | ||||
Obesity (BMI ≥30 kg m−2) | 33 (39) | 36 (38) | 17 (41) | 0.823# |
CRSwNP | 2 (2) | 1 (2) | 1 (2) | 1.000# |
CRSsNP | 14 (17) | 4 (10) | 10 (24) | 0.079# |
ASA intolerance | 4 (5) | 2 (5) | 2 (5) | 1.000# |
Atopic dermatitis | 4 (5) | 1 (2) | 3 (7) | 0.305# |
Cardiovascular diseases | 11 (13) | 6 (14) | 5 (12) | 0.746# |
Diabetes | 3 (4) | 0 (0) | 3 (7) | 0.078# |
Reflux | 5 (6) | 2 (5) | 3 (7) | 0.645# |
Allergic rhinitis | 2 (2) | 0 (0) | 2 (5) | 0.152# |
Data are presented as n (%) or median (interquartile range), unless otherwise stated. p-values were derived using t-test, if not indicated otherwise. SEA: severe eosinophilic asthma; BMI: body mass index; IL: interleukin; OCS: oral corticosteroids; ICS: inhaled corticosteroids; PFT: pulmonary function testing; DLCO: diffusing capacity for carbon monoxide; KCO: carbon monoxide transfer coefficient; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BDT: bronchodilator test; CT: computed tomography; LAA: low-attenuation areas; CRSwNP: chronic rhinosinusitis with nasal polyps; CRSsNP: chronic rhinosinusitis without nasal polyps; ASA: acetylsalicylic acid. #: Chi squared test; ¶: data from n=56 patients available; +: data from n=45 patients available. Significant values are marked as bold.